Clinical trials
Gastroesophageal Junction Adenocarcinoma clinical trials
Below are recruiting gastroesophageal junction adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 177 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06793917RecruitingPhase 3
Immunotherapy plus chemo vs. chemo alone for advanced stomach cancer
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
Fuzhou, FujianAges 18–70 - NCT06529822RecruitingPhase 1
Personalized cancer vaccine for solid tumors with residual disease
This trial tests a personalized cancer vaccine designed to help your immune system fight any remaining cancer cells after surgery. It is for people with certain solid tumors—like bladder, stomach, melanoma, or lung cancer—that show signs of disease through a blood test.
Orlando, FloridaAges 18 years+ - NCT05872295RecruitingPhase 1
Study drug for HER2-positive advanced cancers
This Phase 1 trial tests IKS014 to see how safe it is and how well it works in advanced solid tumors that have HER2. You may be eligible if your tumor is HER2-positive (including certain “low HER2” types) and your body’s blood counts and organ function are strong enough.
Newport Beach, CaliforniaAges 18 years+ - NCT05671822RecruitingPhase 2
Study of targeted drugs for HER2-positive advanced stomach cancer
This Phase 2 trial tests whether SHR-A1811—given with other medicines—works safely and effectively for people with advanced stomach or gastroesophageal junction cancer that has high HER2. It may help shrink tumors or slow cancer growth, especially if previous treatment didn’t work.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05187182RecruitingPhase 1
Testing a new cancer drug with FOLFOX and immune therapy
This Phase 1 study tests CA-4948 given with standard chemotherapy (FOLFOX) and an immune therapy (an immune checkpoint inhibitor, similar to PD-1). It’s for people with advanced stomach or esophageal cancer that can’t be removed by surgery, to see how well the treatment works and whether it’s safe.
St Louis, MissouriAges 18 years+ - NCT03526835RecruitingPhase 1/Phase 2
Study of MCLA-158 for advanced solid tumors
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
La Jolla, CaliforniaAges 18 years+ - NCT06300879Recruiting
New surgery technique for upper stomach or junction cancer
This study tests a new surgical technique for removing cancer in the upper stomach or where the stomach meets the esophagus. It aims to see if this technique is safe and effective for people with early-stage adenocarcinoma who haven't had other cancer treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04455282Recruiting
Blood test-guided surgery for gastroesophageal cancer
This trial studies blood-based biomarkers to help doctors choose the best individualized surgical treatment for gastroesophageal junction adenocarcinoma. If you qualify, you’ll get standard care plus additional testing to see whether the blood results can guide surgery more precisely.
Cologne, North Rhine-WestphaliaAges 18 years+ - NCT03539822RecruitingPhase 1/Phase 2
Cabozantinib and immunotherapy for advanced stomach or bowel cancers
This early-phase study tests a combination of anti-cancer pills and immune-based treatment for people with advanced stomach, esophagus, colorectal, or liver cancer. It aims to shrink tumors and see how safe the treatment is, including whether biopsy testing can help guide future care.
Westwood, KansasAges 18 years+
Hear when a new Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastroesophageal junction adenocarcinoma?
- Yes. Clin2 currently lists 177 recruiting gastroesophageal junction adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastroesophageal junction adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastroesophageal junction adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Gastric / Gastroesophageal Junction Adenocarcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal Junction (GEJ) Adenocarcinoma
- Advanced Gastroesophageal Junction Adenocarcinoma
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Locally Advanced Gastroesophageal Junction Adenocarcinoma
- Unresectable Gastroesophageal Junction Adenocarcinoma
- AFP Gastric or Gastroesophageal Junction Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.